The latest price target for Aclaris Therapeutics (NASDAQ:ACRS) was reported by Leerink Partners on November 19, 2024. The analyst firm set a price target for $7.00 expecting ACRS to rise to within 12 months (a possible 152.71% upside). 10 analyst firms have reported ratings in the last year.

The latest analyst rating for Aclaris Therapeutics (NASDAQ:ACRS) was provided by Leerink Partners, and Aclaris Therapeutics upgraded their outperform rating.

The last upgrade for Aclaris Therapeutics Inc happened on November 19, 2024 when Leerink Partners raised their price target to $7. Leerink Partners previously had a market perform for Aclaris Therapeutics Inc.

The last downgrade for Aclaris Therapeutics Inc happened on January 22, 2024 when HC Wainwright & Co. changed their price target from N/A to N/A for Aclaris Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aclaris Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aclaris Therapeutics was filed on November 19, 2024 so you should expect the next rating to be made available sometime around November 19, 2025.

While ratings are subjective and will change, the latest Aclaris Therapeutics (ACRS) rating was a upgraded with a price target of $2.00 to $7.00. The current price Aclaris Therapeutics (ACRS) is trading at is $2.77, which is within the analyst’s predicted range.